Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioNotebook: Ambit, Xencor, Soligenix, Ampio

This article was originally published in Scrip

Executive Summary

Ambit stock drops on no accelerated filing for quizartinib; Xencor prices IPO, rises in first day; Soligenix starts Phase II orBec study; and Ampio updates Phase III Ampion status.

Advertisement

Related Content

Novartis Deal Gives Xencor $150m Up Front, Up To $2.41bn In Milestone Fees

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC023662

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel